Get email updates from SABCSMeetingNews.org
Subscribe to get regular news updates from SABCS.org and SABCS Meeting News.
The final day of SABCS 20 included the session “View from the Trenches: What Will You Do on Monday Morning,” featuring a multidisciplinary panel of experts who discussed some of the most important data and study findings presented during the meeting.
In this year’s William L. McGuire Memorial Lecture, Mary-Claire King, PhD, called for universal testing of women for BRCA1 and BRCA 2 mutations to prevent breast and ovarian cancer.
Large prospective cohort studies have provided valuable insights into breast cancer risk at the population level. But broad characteristics such as age, body mass index, type of cancer, age at diagnosis, and progression are just the beginning.
Tumor infiltrating lymphocytes are an immunologic novelty that is moving toward clinical utility in breast cancer prognosis and treatment selection. In her AACR Award Lecture, Sherene Loi, PhD, FRACP, described ongoing research into the role of TILs in breast cancer prognosis and progression.
Use the SABCS mobile app to complete session surveys and evaluations for the sessions you attended. Please be sure to go through the entire survey to ensure you receive the proper credit.
With the SABCS 20 Virtual Symposium in the books, the SABCS Executive and Program Planning committees would like to thank everyone who participated in planning and presenting this year’s meeting, and a special thanks to everyone across the globe who attended.
It is certainly no understatement to say that 2020 has been a very tough year in many ways, but it has not stopped scientific progress and the great strides and studies that have been reported over the course of the year.
Should all breast cancer patients have germline genetic testing? That is a topic getting a lot of attention and was the question tackled by a pair of expert clinician-scientists during a special SABCS 20 debate.
The I-SPY trials have become models to accelerate the development of personalized treatment for breast cancer patients. In this year’s Brinker Clinical Research Award Lecture, I-SPY Principal Investigator Laura Esserman, MD, MBA, discussed the vision and goals for I-SPY 2 and beyond.
As one of the world’s leading experts in the science of estrogen receptor signaling and a pioneer in the development of SERMs and SERDs, Donald McDonnell, PhD, says one of the questions he is asked most frequently is which of these is most suitable and most likely to work best in metastatic breast cancer.